Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kailera Therapeutics, Inc.KLRA · Entity 4435 | Director · 10% owner | April 16, 2026 | April 20, 2026 |
| Surgery Partners, Inc.SGRY · Entity 4534 | Director · 10% owner | December 19, 2023 | December 22, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kailera Therapeutics, Inc.
Report date April 16, 2026 · Filed April 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 26,255,581 |
Last balance in matching sequence
After 2026-04-20 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-04-20 · Conversion · Acquired 17,857,143 · Balance 17,857,143 F1: Each share of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date. F3: Represents securities held directly by BCPE Perseus Investor, LP ("BCPE Perseus"). F4: Mr. Kaplan is a Partner of Bain Capital Investors, LLC ("BCI"). BCI is the ultimate general partner of BCPE Perseus. As a result, Mr. Kaplan may be deemed to share voting and dispositive power with respect to the securities held by BCPE Perseus. Mr. Kaplan disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Row 2 · 2026-04-20 · Purchase · Acquired 8,398,438 · Balance 26,255,581 F3: Represents securities held directly by BCPE Perseus Investor, LP ("BCPE Perseus"). F4: Mr. Kaplan is a Partner of Bain Capital Investors, LLC ("BCI"). BCI is the ultimate general partner of BCPE Perseus. As a result, Mr. Kaplan may be deemed to share voting and dispositive power with respect to the securities held by BCPE Perseus. Mr. Kaplan disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnotes | 0 |
Reported balance
After 2026-04-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-20 · Conversion · Disposed 17,857,143 · Balance 0 F1: Each share of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date. F3: Represents securities held directly by BCPE Perseus Investor, LP ("BCPE Perseus"). F4: Mr. Kaplan is a Partner of Bain Capital Investors, LLC ("BCI"). BCI is the ultimate general partner of BCPE Perseus. As a result, Mr. Kaplan may be deemed to share voting and dispositive power with respect to the securities held by BCPE Perseus. Mr. Kaplan disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2036-04-16 | Direct | 38,300 |
Reported balance
After 2026-04-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-04-16 · Grant · Acquired 38,300 · Balance 38,300 F2: The options vest and become exercisable as to 100% of the underlying shares on April 16, 2027, subject to Mr. Kaplan's continued service through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date.
F2: The options vest and become exercisable as to 100% of the underlying shares on April 16, 2027, subject to Mr. Kaplan's continued service through each such vesting date.
F3: Represents securities held directly by BCPE Perseus Investor, LP ("BCPE Perseus").
F4: Mr. Kaplan is a Partner of Bain Capital Investors, LLC ("BCI"). BCI is the ultimate general partner of BCPE Perseus. As a result, Mr. Kaplan may be deemed to share voting and dispositive power with respect to the securities held by BCPE Perseus. Mr. Kaplan disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
Surgery Partners, Inc.
Report date December 19, 2023 · Filed December 22, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 49,946,972 |
Last balance in matching sequence
After 2023-12-19 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2023-12-19 · Sale · Disposed 7,826,870 · Balance 50,421,379 F1: Represents shares of Common Stock held directly by BCPE Seminole Holdings LP ("BCPE Seminole"), BCPE Seminole Holdings II Intermediate LP ("BCPE Seminole II"), BCPE Seminole Holdings III, L.P. ("BCPE Seminole III") and BCPE Seminole Holdings IV, L.P. ("BCPE Seminole IV" and, together with BCPE Seminole, BCPE Seminole II and BCPE Seminole III, the "Bain Capital Entities"). F2: Bain Capital Investors, LLC ("BCI") is the sole member of (i) BCPE Seminole GP LLC, which is the general partner of BCPE Seminole and BCPE Seminole IV, (ii) BCPE Seminole GP II LLC, which is the general partner of BCPE Seminole II, and (iii) BCPE Seminole GP III LLC, which is the general partner of BCPE Seminole III. Mr. Kaplan is a Partner of BCI. By virtue of the relationships described in these footnotes, Mr. Kaplan may be deemed to share voting and dispositive power with respect to the shares of Common Stock held by the Bain Capital Entities. Mr. Kaplan disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Row 2 · 2023-12-19 · Other · Disposed 474,407 · Balance 49,946,972 F3: On December 19, 2023, BCPE Seminole distributed 474,407 shares of Common Stock to one or more members or partners in connection with certain charitable gifts made by such members or partners or their direct or indirect owners. F1: Represents shares of Common Stock held directly by BCPE Seminole Holdings LP ("BCPE Seminole"), BCPE Seminole Holdings II Intermediate LP ("BCPE Seminole II"), BCPE Seminole Holdings III, L.P. ("BCPE Seminole III") and BCPE Seminole Holdings IV, L.P. ("BCPE Seminole IV" and, together with BCPE Seminole, BCPE Seminole II and BCPE Seminole III, the "Bain Capital Entities"). F2: Bain Capital Investors, LLC ("BCI") is the sole member of (i) BCPE Seminole GP LLC, which is the general partner of BCPE Seminole and BCPE Seminole IV, (ii) BCPE Seminole GP II LLC, which is the general partner of BCPE Seminole II, and (iii) BCPE Seminole GP III LLC, which is the general partner of BCPE Seminole III. Mr. Kaplan is a Partner of BCI. By virtue of the relationships described in these footnotes, Mr. Kaplan may be deemed to share voting and dispositive power with respect to the shares of Common Stock held by the Bain Capital Entities. Mr. Kaplan disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of Common Stock held directly by BCPE Seminole Holdings LP ("BCPE Seminole"), BCPE Seminole Holdings II Intermediate LP ("BCPE Seminole II"), BCPE Seminole Holdings III, L.P. ("BCPE Seminole III") and BCPE Seminole Holdings IV, L.P. ("BCPE Seminole IV" and, together with BCPE Seminole, BCPE Seminole II and BCPE Seminole III, the "Bain Capital Entities").
F2: Bain Capital Investors, LLC ("BCI") is the sole member of (i) BCPE Seminole GP LLC, which is the general partner of BCPE Seminole and BCPE Seminole IV, (ii) BCPE Seminole GP II LLC, which is the general partner of BCPE Seminole II, and (iii) BCPE Seminole GP III LLC, which is the general partner of BCPE Seminole III. Mr. Kaplan is a Partner of BCI. By virtue of the relationships described in these footnotes, Mr. Kaplan may be deemed to share voting and dispositive power with respect to the shares of Common Stock held by the Bain Capital Entities. Mr. Kaplan disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
F3: On December 19, 2023, BCPE Seminole distributed 474,407 shares of Common Stock to one or more members or partners in connection with certain charitable gifts made by such members or partners or their direct or indirect owners.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 20, 2026 Filed Apr 20, 2026 22:00 UTC | Kailera Therapeutics, Inc. KLRA · Entity 4435 | ConversionSeries B Preferred Stock · Derivative | 17,857,143 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-164388 · ownership.xml · derivative · entry 3 Kaplan Andrew T. · CIK 0001752059 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 17,857,143 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date. F1 · derivative.exercise_date: Each share of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date. F1 · derivative.expiration_date: Each share of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date. F3 · ownership.nature: Represents securities held directly by BCPE Perseus Investor, LP ("BCPE Perseus"). F4 · ownership.nature: Mr. Kaplan is a Partner of Bain Capital Investors, LLC ("BCI"). BCI is the ultimate general partner of BCPE Perseus. As a result, Mr. Kaplan may be deemed to share voting and dispositive power with respect to the securities held by BCPE Perseus. Mr. Kaplan disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| April 20, 2026 Filed Apr 20, 2026 22:00 UTC | Kailera Therapeutics, Inc. KLRA · Entity 4435 | PurchaseCommon Stock | 8,398,438 | $16.00 | $134,375,008.00 |
DisclosureSEC source: 0001193125-26-164388 · ownership.xml · nonDerivative · entry 2 Kaplan Andrew T. · CIK 0001752059 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 26,255,581 F3 · ownership.nature: Represents securities held directly by BCPE Perseus Investor, LP ("BCPE Perseus"). F4 · ownership.nature: Mr. Kaplan is a Partner of Bain Capital Investors, LLC ("BCI"). BCI is the ultimate general partner of BCPE Perseus. As a result, Mr. Kaplan may be deemed to share voting and dispositive power with respect to the securities held by BCPE Perseus. Mr. Kaplan disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| April 20, 2026 Filed Apr 20, 2026 22:00 UTC | Kailera Therapeutics, Inc. KLRA · Entity 4435 | ConversionCommon Stock | 17,857,143 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-164388 · ownership.xml · nonDerivative · entry 1 Kaplan Andrew T. · CIK 0001752059 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 17,857,143 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date. F3 · ownership.nature: Represents securities held directly by BCPE Perseus Investor, LP ("BCPE Perseus"). F4 · ownership.nature: Mr. Kaplan is a Partner of Bain Capital Investors, LLC ("BCI"). BCI is the ultimate general partner of BCPE Perseus. As a result, Mr. Kaplan may be deemed to share voting and dispositive power with respect to the securities held by BCPE Perseus. Mr. Kaplan disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| April 16, 2026 Filed Apr 20, 2026 22:00 UTC | Kailera Therapeutics, Inc. KLRA · Entity 4435 | GrantStock Option (right to buy) · Derivative | 38,300 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001193125-26-164388 · ownership.xml · derivative · entry 4 Kaplan Andrew T. · CIK 0001752059 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,300 Underlying: Common Stock · 38,300 shares Expires 2036-04-16 F2 · derivative.exercise_date: The options vest and become exercisable as to 100% of the underlying shares on April 16, 2027, subject to Mr. Kaplan's continued service through each such vesting date. Read SEC document |
| December 19, 2023 Filed Dec 22, 2023 01:29 UTC | Surgery Partners, Inc. SGRY · Entity 4534 | OtherCommon Stock | 474,407 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-072382 · ownership.xml · nonDerivative · entry 2 Kaplan Andrew T. · CIK 0001752059 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 49,946,972 F3 · kind: On December 19, 2023, BCPE Seminole distributed 474,407 shares of Common Stock to one or more members or partners in connection with certain charitable gifts made by such members or partners or their direct or indirect owners. F1 · ownership.nature: Represents shares of Common Stock held directly by BCPE Seminole Holdings LP ("BCPE Seminole"), BCPE Seminole Holdings II Intermediate LP ("BCPE Seminole II"), BCPE Seminole Holdings III, L.P. ("BCPE Seminole III") and BCPE Seminole Holdings IV, L.P. ("BCPE Seminole IV" and, together with BCPE Seminole, BCPE Seminole II and BCPE Seminole III, the "Bain Capital Entities"). F2 · ownership.nature: Bain Capital Investors, LLC ("BCI") is the sole member of (i) BCPE Seminole GP LLC, which is the general partner of BCPE Seminole and BCPE Seminole IV, (ii) BCPE Seminole GP II LLC, which is the general partner of BCPE Seminole II, and (iii) BCPE Seminole GP III LLC, which is the general partner of BCPE Seminole III. Mr. Kaplan is a Partner of BCI. By virtue of the relationships described in these footnotes, Mr. Kaplan may be deemed to share voting and dispositive power with respect to the shares of Common Stock held by the Bain Capital Entities. Mr. Kaplan disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| December 19, 2023 Filed Dec 22, 2023 01:29 UTC | Surgery Partners, Inc. SGRY · Entity 4534 | SaleCommon Stock | 7,826,870 | $33.44 | $261,730,532.80 |
DisclosureSEC source: 0000950170-23-072382 · ownership.xml · nonDerivative · entry 1 Kaplan Andrew T. · CIK 0001752059 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 50,421,379 F1 · ownership.nature: Represents shares of Common Stock held directly by BCPE Seminole Holdings LP ("BCPE Seminole"), BCPE Seminole Holdings II Intermediate LP ("BCPE Seminole II"), BCPE Seminole Holdings III, L.P. ("BCPE Seminole III") and BCPE Seminole Holdings IV, L.P. ("BCPE Seminole IV" and, together with BCPE Seminole, BCPE Seminole II and BCPE Seminole III, the "Bain Capital Entities"). F2 · ownership.nature: Bain Capital Investors, LLC ("BCI") is the sole member of (i) BCPE Seminole GP LLC, which is the general partner of BCPE Seminole and BCPE Seminole IV, (ii) BCPE Seminole GP II LLC, which is the general partner of BCPE Seminole II, and (iii) BCPE Seminole GP III LLC, which is the general partner of BCPE Seminole III. Mr. Kaplan is a Partner of BCI. By virtue of the relationships described in these footnotes, Mr. Kaplan may be deemed to share voting and dispositive power with respect to the shares of Common Stock held by the Bain Capital Entities. Mr. Kaplan disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.